Non-small cell lung cancer stage III
RecruitingStudy of accelerated chemoradiotherapy followed by durvalumab treatment in patients with locally advanced non-small-cell lung cancer (NSCLC) using PET imaging guidance
Study of accelerated chemoradiotherapy followed by durvalumab treatment in patients with locally advanced non-small-cell lung cancer (NSCLC) using PET imaging guidance
- Disease:Non-small cell lung cancer stage III
- Substances:Durvalumab
Germany- Participants:18–64 years · 65+ years
- Substances:Durvalumab










